Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab
CARDIOLOGY IN THE YOUNG, vol.29, no.4, pp.549-551, 2019 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 29 Issue: 4
- Publication Date: 2019
- Doi Number: 10.1017/s1047951119000672
- Journal Name: CARDIOLOGY IN THE YOUNG
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.549-551
- Keywords: Idiopathic recurrent pericarditis, treatment, anti-IL 1 agents, RECEPTOR ANTAGONIST ANAKINRA
- Istanbul University-Cerrahpasa Affiliated: No
Abstract
Conventional algorithm for treatment of pericarditis and prevention of recurrences consists of non-steroid anti-inflammatory drugs and/or colchicine, followed by corticosteroids in resistant patients. Anakinra has emerged as a promising and safe treatment modality for steroid-dependent idiopathic recurrent pericarditis. However, the efficacy and safety of canakinumab, another anti-interleukin-1 agent, has not been assessed up to date. Herein, we present development of an anaphylactic reaction due to anakinra and a successful subsequent treatment with canakinumab for the first time in the literature.